From clinical trial site to one of the few institutions in the country authorized to deliver all available FDA-approved CAR T-cell therapies, Fox Chase Cancer Center describes its successful evolution and identifies effective practices to help community cancer centers surmount the financial barriers to therapy as well as build strong referral networks with institutions offering cellular therapies.

To help address challenges in navigating clinical trial conversations with patients, the ACCC Community Oncology Research Institute developed a practical, quick-reference resource that offers conversation guidance, suggested patient-friendly language, responses to common questions and concerns, and educational resources to support communication across the multidisciplinary cancer care team.

By championing and encouraging advanced practice providers and allied health professionals to work at the top of their licenses, Wilmot Cancer Institute offers comprehensive care close to home through its breast care program that vastly improves the patient experience.

On the final day of the 43rd National Oncology Conference, a series of interactive panel discussions explored innovative strategies for remote patient monitoring across the globe, improving quality and safety amidst complex treatments, financial challenges in precision medicine and clinical trials, and more.

Day two of the 43rd National Oncology Conference featured lively panel discussions on operationalizing CAR T-cell therapy and bispecific antibodies, building sustainable supportive care services, expanding access amid rising patient volumes, as well as presentations from the six 2026 ACCC Innovator Award Winners.
